Κατεύθυνση Κλινική και Πειραματική Νευροχειρουργική
Library of the School of Health Sciences

2024-04-17

2024

Mousa Danai-Priskila

Καλαματιανός Θεοδόσιος, Ακαδημαϊκός Υπότροφος, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Πιπέρη Χριστίνα, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Στράντζαλης Γεώργιος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Κινάση του Αναπλαστικού Λεμφώματος σε όγκους ΚΝΣ εκτός των γλοιακών, νευρογλοιακών και νευρωνικών νεοπλασμάτων

Greek

Anaplastic Lymphoma Kinase in CNS tumors other than gliomas, glioneuronal and neuronal tumors

Central nervous system (CNS) tumours cause significant mortality and morbidity at all ages and are now categorised according to their histopathological features and aggressiveness. Environmental as well as genetic factors seem to account for a large proportion of their occurrence. Tumours occurring in the posterior cranial fossa are difficult to access and their growth brings many complications to the human body. Anaplastic lymphoma kinase (ALK) is a protein that is being studied in order to broaden the prognostic, diagnostic and therapeutic horizons of these tumors.
Objectives: Aim of the study was to map the available literature on the role of ALK in non-glial tumors of the posterior cranial fossa and to identify diagnostic, prognostic and therapeutic considerations.
Material and Methods: Following the PRISMA-ScR guidelines, studies investigating the role of ALK in primary non-glial tumors of the posterior cranial fossa were included. A total of 210 manuscripts were selected for full text review and 16 eventually met the inclusion criteria.
Results: The review included 55 cases of primary, intracranial tumors of the posterior cranial fossa with genetic alterations and/or alterations in ALK protein expression. ALK pathology was investigated by immunohistochemistry and genetic analysis. Several studies provided evidence for the diagnostic and prognostic value of ALK, as well as for the therapeutic efficacy in targeting it.
Conclusions: It is observed that ALK testing may help in the diagnosis and prediction of the outcome of some of these tumors, particularly myeloblastoma (WNT-activated). Interestingly, a significant proportion of ALK-positive/mutated CNS histiocytes are localized in the posterior cranial fossa. These findings suggest the potential benefits of targeting ALK in the treatment of certain brain tumors, a promising area for future research.

Health Sciences

Anaplastic Lymphoma Kinase (ALK), Medulloblastoma, Histiocytosis, Central nervous system, ALK inhibition

No

0

Yes

161

83

File access is restricted until 2024-10-17.

https://pergamos.lib.uoa.gr/uoa/dl/object/3396319